# Harrow, Inc. (HROW) Stock Analysis: Eyeing a 60.87% Upside with Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/harrow-inc-hrow-stock-analysis-eyeing-a-60-87-upside-with-strong-buy-ratings/4121213722
- Published: 2025-08-26T10:40:53+01:00
- Author: Madison Wilson

Harrow, Inc. (NASDAQ: HROW), a prominent player in the healthcare sector specializing
in ophthalmic pharmaceutical products, offers an intriguing investment opportunity.
With a market capitalization of $1.38 billion, Harrow is strategically positioned
within the drug manufacturers’ space, focusing on specialty and generic products
for eyecare. The company, headquartered in Nashville, Tennessee, has transformed
its brand image recently, changing its name from Harrow Health, Inc. to Harrow, 
Inc. in September 2023.

Despite a recent price dip of 0.04% to $37.36, Harrow’s stock presents a compelling
case for investors. The stock has experienced significant volatility over the past
year, trading within a range of $22.20 to $57.48. However, the current price remains
well above both its 50-day and 200-day moving averages, which stand at $34.02 and
$31.96, respectively. This technical strength, combined with a 14-day RSI of 49.32,
suggests a balanced momentum, neither overbought nor oversold.

One of the standout figures for Harrow is the substantial potential upside of 60.87%,
as indicated by the average target price of $60.10 set by analysts. With eight buy
ratings and no holds or sells, market sentiment leans decisively bullish. This optimism
is underpinned by a robust revenue growth rate of 30.20%, although the company is
currently operating at a net loss with an EPS of -0.28 and a return on equity of-
19.03%.

The company’s forward P/E ratio of 15.27 suggests that investors anticipate improved
profitability in the near future, particularly as Harrow continues to capitalize
on its diverse product portfolio. Key offerings include IHEEZO, an ophthalmic gel,
as well as a range of solutions such as IOPIDINE and VEVYE for various eye conditions.
This comprehensive array of products positions Harrow to address a broad spectrum
of ophthalmic needs, from inflammation and bacterial infections to more complex 
surgeries.

Harrow’s strategic emphasis on niche pharmaceutical markets is bolstered by its 
free cash flow position, albeit currently negative at -$28 million, indicating ongoing
investments in product development and market expansion. While the absence of a 
dividend yield and payout ratio might deter income-focused investors, growth-oriented
investors could find value in Harrow’s long-term potential.

For those keeping a close eye on execution, Harrow’s MACD of 1.36 and signal line
of 1.20 further support the bullish case, suggesting upward momentum in stock price,
potentially aligning with the optimistic analyst targets.

Investors considering Harrow, Inc. should weigh the company’s growth trajectory 
against its current financial challenges. The promising analyst ratings and significant
upside potential make Harrow an appealing candidate for those looking to invest 
in the dynamic and innovative segment of eyecare pharmaceuticals. As the company
moves forward, its ability to convert revenue growth into profitability will be 
a crucial factor to watch.

Share on: